Dr. Hadi Shafiee, one of the lead researchers, explains, “Finding an HIV particle in human blood is like trying to find an ice cube in a jelly-filled Olympic pool while blindfolded.” ...

Media Contact Diana Yates University of Illinois at Urbana-Champaign, News Bureau [email protected] Office: 217-333-5802 ...

Interestingly, each HIV particle has many more human HLA on its envelope surface than it has its own gp120 viral coat proteins, which the virus needs to bind to CD4 and CCR5 or CXCR4 on the lymphocyte ...

An early trial for an experimental HIV vaccine candidate has shown promising results. 97% of recipients in a phase 1 study showed immune system activity in response to the vaccine.

These rafts--so named because they are insoluble in nonionic detergent--are domains within a cell membrane. The HIV glycosaminoglycan (Gag) proteins occupy these rafts. To build a new HIV particle, ...

Researchers have identified a positive correlation between viral load and the rate at which genetic diversity increases within intrahost HIV populations. HIV has been historically difficult to treat ...

Collab with Moderna This vaccine is supposed to be the first in a sequence of several doses, each conditioning the immune system with a distinct HIV particle. As the shots continue, the molecules ...

The top row shows, left to right, red-labeled protein molecules named Gag (shown here in black and white) assembling to form a new HIV particle that buds from a human cell grown in the laboratory.

Researchers at CIDR, led by Yuntao Wu, professor in George Mason's School of Systems Biology and the principal investigator of the NIH-funded study, developed a special HIV-like virus particle ...

Dr. Hadi Shafiee, one of the lead researchers, explains, “Finding an HIV particle in human blood is like trying to find an ice cube in a jelly-filled Olympic pool while blindfolded.” ...